Factors associated with use of bone morphogenetic protein during pediatric spinal fusion surgery: an analysis of 4817 patients
- PMID: 23864174
- DOI: 10.2106/JBJS.L.01118
Factors associated with use of bone morphogenetic protein during pediatric spinal fusion surgery: an analysis of 4817 patients
Abstract
Background: Our goal was to investigate whether the use of recombinant human bone morphogenetic protein (rhBMP, or BMP) during pediatric spinal fusion surgery has been increasing and how patient, surgical, and hospital characteristics influence BMP use.
Methods: Using the Nationwide Inpatient Sample database, we identified 4817 children eighteen years old or younger who had undergone spinal fusion surgery with the use of BMP from 2003 through 2009. A multivariate logistic regression model, the Z-test of proportions, and simple linear regression were used for statistical analysis (significance, p < 0.05).
Results: There was a 3.4-fold increase in BMP use, from 2.7% in 2003 to 9.3% in 2009-an average 16% per year increase (p < 0.01). For each additional year of age, BMP use increased 1.09-fold (odds ratio [OR]: 1.05 to 1.13, p < 0.01). Compared with BMP use for adolescent idiopathic scoliosis, the adjusted odds of BMP use were increased 1.3-fold for congenital scoliosis (OR: 1.02 to 1.76, p = 0.04), 2.8-fold for thoracolumbar fractures (OR: 2.1 to 3.8, p < 0.01), and 5.0-fold for spondylolisthesis (OR: 3.9 to 6.3, p < 0.01). Patients with private insurance were 1.5-fold more likely to receive BMP (OR: 1.2 to 1.9, p < 0.01). Patients in whom autograft bone was used intraoperatively were 0.63-fold less likely to receive BMP (OR: 0.52 to 0.77, p < 0.01). The rate of BMP use was 0.38-fold lower in teaching hospitals (OR: 0.31 to 0.48, p < 0.01) and 1.7-fold higher in hospitals with a large bed capacity (OR: 1.3 to 2.2, p < 0.01). Compared with hospitals located in the Northeast, those in the West had a 1.7-fold increase (OR: 1.3 to 2.4, p < 0.01) and those in the South had a 2.0-fold increase (OR: 1.5 to 2.7, p < 0.01) in the odds of BMP use.
Conclusions: Use of BMP during pediatric spinal fusion has increased significantly. Patient factors (age, diagnosis, and insurance), surgical factors (autograft use), and hospital factors (teaching status, bed capacity, and location) influenced the variation in BMP use.
Comment in
-
Is off-label use of BMP in pediatric spine surgery now a standard of care? Commentary on an article by Amit Jain, MD, et al.: "Factors associated with use of bone morphogenetic protein during pediatric spinal fusion surgery. an analysis of 4817 patients".J Bone Joint Surg Am. 2013 Jul 17;95(14):e103 1-2. doi: 10.2106/JBJS.M.00320. J Bone Joint Surg Am. 2013. PMID: 23864186 No abstract available.
Similar articles
-
Impact of bone morphogenetic proteins on frequency of revision surgery, use of autograft bone, and total hospital charges in surgery for lumbar degenerative disease: review of the Nationwide Inpatient Sample from 2002 to 2008.Spine J. 2014 Jan;14(1):20-30. doi: 10.1016/j.spinee.2012.10.035. Epub 2012 Dec 5. Spine J. 2014. PMID: 23218827
-
Nationwide practice patterns in the use of recombinant human bone morphogenetic protein-2 in pediatric spine surgery as a function of patient-, hospital-, and procedure-related factors.J Neurosurg Pediatr. 2014 Nov;14(5):476-85. doi: 10.3171/2014.7.PEDS1499. Epub 2014 Aug 29. J Neurosurg Pediatr. 2014. PMID: 25171721
-
Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011.Spine (Phila Pa 1976). 2014 Mar 15;39(6):491-6. doi: 10.1097/BRS.0000000000000167. Spine (Phila Pa 1976). 2014. PMID: 24365905
-
Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: an analysis of 4658 patients and review of the literature.J Neurosurg Pediatr. 2014 Dec;14(6):635-43. doi: 10.3171/2014.8.PEDS13665. Epub 2014 Oct 10. J Neurosurg Pediatr. 2014. PMID: 25303159 Review.
-
Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion.J Neurosurg Spine. 2014 Jul;21(1):106-32. doi: 10.3171/2014.4.SPINE14325. J Neurosurg Spine. 2014. PMID: 24980593 Review.
Cited by
-
Novel Surgical Technique for Adolescent Idiopathic Scoliosis: Minimally Invasive Scoliosis Surgery.J Clin Med. 2022 Oct 2;11(19):5847. doi: 10.3390/jcm11195847. J Clin Med. 2022. PMID: 36233714 Free PMC article. Review.
-
Drilling Combined with Adipose-derived Stem Cells and Bone Morphogenetic Protein-2 to Treat Femoral Head Epiphyseal Necrosis in Juvenile Rabbits.Curr Med Sci. 2018 Apr;38(2):277-288. doi: 10.1007/s11596-018-1876-3. Epub 2018 Apr 30. Curr Med Sci. 2018. PMID: 30074186
-
Treatment of pediatric spinal deformity with use of recombinant human bone morphogenetic protein-2.J Mater Sci Mater Med. 2018 Jun 25;29(7):93. doi: 10.1007/s10856-018-6104-y. J Mater Sci Mater Med. 2018. PMID: 29938328
-
Bone morphogenetic protein in pediatric spine fusion surgery.J Spine Surg. 2016 Mar;2(1):9-12. doi: 10.21037/jss.2016.01.06. J Spine Surg. 2016. PMID: 27683689 Free PMC article. Review.
-
Effectiveness and safety of recombinant human bone morphogenetic protein-2 for adults with lumbar spine pseudarthrosis following spinal fusion surgery: A systematic review.Bone Joint Res. 2016 Apr;5(4):145-52. doi: 10.1302/2046-3758.54.2000418. Bone Joint Res. 2016. PMID: 27121215 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
